By Brad Sorensen, CFA NASDAQ:ENSC READ THE FULL ENSC RESEARCH REPORT Ensysce Biosciences (NASDAQ:ENSC) is a clinical stage company that is developing treatments designed to have the same pain-relieving capabilities as opioids but come with the ability to inhibit abuse and overdoses. Opioid abuse is a national crisis, with the CDC estimating over 75,000 deaths … Read more
By M. Marin NASDAQ:EZFL Advancing strategy to be a leading on-demand mobile fueling company… EzFill Holdings (NASDAQ:EZFL) provides a mobile fuel delivery service that offers convenience to owners of commercial fleets and consumer vehicles. Its target market ranges from individual automobile owners to business fleets. The company brings refueling to the vehicles at their primary … Read more
By David Bautz, PhD NASDAQ:EDSA READ THE FULL EDSA RESEARCH REPORT Business Update Advancing EB06 for Treating Vitiligo Edesa Biotech, Inc. (NASDAQ:EDSA) is planning for a Phase 2 study of its anti-CXCL10 monoclonal antibody for the treatment of moderate-to-severe non-segmental vitiligo patients. Vitiligo is a disease that causes areas of the skin to lose color, … Read more
By Brian Lantier, CFA NASDAQ:CBAT READ THE FULL CBAT RESEARCH REPORT CBAK (NASDAQ:CBAT) has made a number of announcements recently which may not be fully appreciated by the market and which we believe that the shares currently provide an opportunity for patient investors seeking growth at a reasonable price. • In late December, CBAK noted that … Read more
By David Bautz, PhD NASDAQ:XFOR READ THE FULL XFOR RESEARCH REPORT Business Update Licensing Agreement with Norgine Includes €28.5 Million Upfront Payment On January 13, 2025, X4 Pharmaceuticals, Inc. (NASDAQ:XFOR) announced an exclusive licensing and supply agreement with Norgine, a European specialty pharmaceutical company that generates greater than €500 million in annual revenues, that covers Europe, … Read more
